GET A PIECE OF IHEALTHSCREEN
AI-Driven Disease Screening Software
$189,865.28 Raised
REASONS TO INVEST
iHealthScreen is entering what we believe is almost an entirely untapped, multi-billion-dollar global market ($9.5B in USA only). With regulatory approvals already achieved in key markets, along with the established reimbursement code for screening in place approved for European and most of the Asian markets, we believe iHealthScreen is poised to successfully commercialize its products. iHealthScreen’s first product, iPredictTM, is market ready, with one patent received and multiple patents pending, and we’re anticipating AMD & DR FDA 510(K) clearances by mid-2023. Already having a large hospital chain as a customer and a licensing agreement is in place with one of the top camera companies in the world, we believe demonstrates traction with key strategic partners.
To the best of our knowledge, iHealthScreen is the first company in the world to receive CE certification for three blinding eye disease screening: AMD, DR, and glaucoma. In addition, iHealthScreen has developed and validated prediction models for strokes, heart attacks, and cardiovascular diseases. We have seen stroke and heart attack prediction accuracy is almost 10% higher than the existing clinically used prediction models (Framingham and CHADS scores), with additional tools in development phase for Alzheimer’s and dementia prediction.
iHealthScreen has been awarded $2.7M in NIH funding, raised $750K as seed funding and we are working on securing additional research grants. We have received one US patent (the first patent in Late AMD prediction), one patent is pending and four provisional patent applications are submitted. The company’s work on retinal disease screening is featured in the world's largest ophthalmology conference ARVO 2018, and the American Academy of Ophthalmology (AAO) 2020. The stroke prediction results were presented at the Society for Brain Mapping Conference 2021.
the pitch
iHealthScreen is bringing low-cost, AI-driven screening software to primary care offices around the world to provide routine access to disease prevention that would otherwise be limited to specialty care. We’ve been awarded $2.7M in NIH funding and are in the process of receiving an additional $6.5M from private investors and research grants, with one patent received and multiple patents pending. Our first product, iPredictTM, has the capability to screen for late age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma, stroke, heart attack, and cardiovascular heart disease, and we have additional tools in development for Alzheimer’s, dementia and hypertensive retinopathy. By facilitating large-scale, low-cost screening, our software presents wide-reaching impact and huge potential for growth.
A New Leader in AI-Driven Disease Prevention
iHealthScreen’s integrated, retinal imaging-based system makes us one of the first companies in the world to receive CE certification, Australian and UAE Health approvals for AMD, DR, and glaucoma screening. We’re already gaining international traction with contracts in the US, EU, Bangladesh, and UAE, and have been collaborating with Global Victoria, Australia.
iHealthScreen is poised to be a leader in this new area of AI-driven disease prevention, providing critical value to individuals, medical providers, and insurance providers and presenting enormous growth potential to investors.
The Problem & Our Solution
Preventative Screening Should Be Easy, Fast, and Accessible
Our current medical systems—the US serving as the most glaring example—cost patients and providers billions of dollars while often failing to improve overall health outcomes, especially at a preventive level. Primary care doctors lack the resources to provide more than the most basic screenings, and most people don’t have the time or resources to schedule regular screenings with specialists. This results in serious health consequences and large financial burdens, for patients, providers, and insurers alike.
*The features shown in the graphic above reflect features for a product that has not received FDA 510K clearance. The product is not currently available to the general public for sale.
iHealthScreen’s software makes preventative screening for ailments such as eye disease, diabetes, cardiovascular disease, heart attack and stroke easy, fast, and accessible. By lowering costs and expanding access, we’re looking to make screening for a larger set of diseases a seamless, built-in component of your annual check-up, especially for aging patients. In addition to our screening software, we’re aiming to add a built-in telemedicine capability to ensure patients can receive immediate care when and wherever needed.
The Market & Our Traction
A Newly Opened, Multi-Billion-Dollar Global Market
The current market size for screening diabetic retinopathy (DR) and age-related macular degeneration (AMD) is projected at $9.5B, in USA only, with the global diabetic population estimated to reach 578 million by 2030, it should be 3x.
(source)
The introduction of CPT code 92229 in 2021 has opened up the screening market, allowing coverage for retinal imaging for the detection or monitoring of disease. As of now, this massive market is almost entirely untapped, we believe less than 1% of the market is taken by companies that have received FDA 510(K) clearance—providing ideal timing for iHealthScreen’s FDA clearance and market entry. FDA 510K application on AMD screening is already submitted. The 510K application for DR screening is in the final stage of submission. The company expects to obtain these two FDA 510K clearances by the middle of this year and achieve an advantageous position to become commercially successful.
iHealthScreen’s first product, iPredictTM, is market ready, with one patent received and multiple patents pending, and we’re anticipating FDA 510(K) clearance by mid-2023. We’re now one of the first companies in the world to receive CE certification for AMD, DR, and glaucoma screening, and have received approval from Health Australia and Health UAE.
We’ve secured a total of $2.7M in NIH funding, which is being applied towards a three-year prospective trial on late AMD prediction, along with a NIH SBIR Phase II grant for stroke prediction. We’ve signed a licensing agreement with iCare in Finland, an agreement with the Bangladesh Diabetes Society to screen 5.5 million registered diabetics in Bangladesh, as well as another with Burjeel Hospital UAE for DR screenings which has 40 clinics in the Gulf region with billions of dollars in revenue (source).
Why Invest
Invest in the Future of Preventive Healthcare
Streamlined, hassle-free disease screening should be a part of every patient’s annual routine. We’re looking at huge potential for growth, scale, and global impact—and we believe now is the perfect time to join us.
Invest in iHealthScreen & help us on our mission to provide low-cost, advanced screening software in primary care offices across the world - help prevent blindness, deaths and disability.
*The features shown in the graphic above reflect features for a product that has not received FDA 510K clearance. The product is not currently available to the general public for sale.
ABOUT
HEADQUARTERS
132-02 89th Av, Suite 214
Richmond Hill, NY 11418
WEBSITE
View Site
iHealthScreen is an AI-driven HIPAA-compliant med-tech company with incoming product traction in several international markets, using AI to Scalably Screen for Retinal Diseases, Stroke, and Heart Disease. Early diagnosis and intervention can prevent blindness, save countless lives & eliminate massive amounts of downstream spending. iHealthScreen is in the pre-revenue stage of development. Some of the information on the campaign page was obtained via the Company's relationship with iHealthScreen Ltd. (Abu Dhabi), which is an LLC, also owned by Alauddin Bhuiyan, PhD, CEO. There is a software license agreement between the two entities, allowing iHealthScreen Ltd. to use the Company's IP and software portfolios.
TEAM
Alauddin Bhuiyan, PhD
Founder and CEO
Dr. Bhuiyan led the developing iPredictTM a HIPAA-compliant AI-powered software tool, which is based on Electronic Health Record (EHR) and telemedicine platform to screen and predict individuals at risk of diabetic retinopathy (DR), Age-related Macular Degeneration (AMD), Glaucoma, heart disease and stroke (https://iPredict.health).
The AMD, DR, and glaucoma screening tools are already CE certified, Abu Dhabi Health and Australian Health approved.
Dr. Bhuiyan is the inventor of the first image-based prediction tool for age-related macular degeneration (AMD). A full US patent is awarded to iHealthScreen Inc. This work was selected as featured work at ARVO 2018, the largest ophthalmology conference in the world. Also, the American Academy of Ophthalmology selected his work for the panel discussion in 2020. His interview can be viewed at https://macularnews.org/2018/06/07/arvo-2018-alauddin-bhuiyan-phd/
Dr. Bhuiyan has received almost $5M Federal and state grants through various stages of his career. He secured more than $2.7M grants (another $2.2M is under consideration) for his company through NIH SBIR grants a Principal Investigator.
Dr. Bhuiyan received his Ph.D. from the University of Melbourne, Australia, one of the top universities in the world (No. 1 in Australia). He joined at the Centre for Eye Research Australia (CERA) as a post-doctoral research fellow in 2009. Following this - in 2011, he joined at Commonwealth Scientific and Industrial Research Organization (CSIRO, which is the inventor of WiFi Technology) as a research scientist.
While at CSIRO, Dr. Bhuiyan developed a software tool that can predict an individual’s genetic association with Alzheimer’s disease, a patented technology currently being used by Neurovision.
As an innovator and technology developer, he has been at the core of medical products and technologies which have transformed the ophthalmic field and are impacting medical care for hundreds of thousands of patients every year.
Dr. Bhuiyan is a holder of multiple issued and pending patents. He has multiple high-impact publications in the field and published more than a hundred research articles, which have been cited by more than a thousand peer-reviewed publications. He is a senior member of IEEE Computer Society and IEEE Engineering in Medicine and Biology. He served on the technical committee for many IEEE conferences and journals.
Travis Millman, MAPP
Strategic Advisor
Travis works 1 hour per week on iHealthscreen
Ms. Kathleen Adams, MBA
Chief Marketing Officer
From market assessment to launch and implementation, I focus on new approaches to healthcare, particularly for life-threatening illnesses. Discoveries and inventions are essential, but not sufficient, to improving healthcare: closing the gap between new capabilities and the realities of care delivery is the only route to meaningful change for the better.
I nurture innovations -- new disease insights, new therapeutic or diagnostic technologies -- by working backward from the patient or provider, while others on the team work forward from the science. I've worked in marketing, business development, technology evaluation and patient advocacy roles at diagnostics companies, clinical laboratories and pharma and biotechnology companies, conducting pre-market evaluations, producing and executing development plans, and leading product launch campaigns for pharmaceutical and diagnostic products, as well as a suite of targeted diagnostic services. I've led commercial teams and strategic initiatives, served on a corporate board and a senior management team, and influenced at the senior executive level to bring about institutional change and enable new approaches to team-driven development.
My experience in establishing coalitions across the for-profit/not-for-profit divide, as well as my interdisciplinary team leadership efforts, are growing in relevance during this period of rapid industry restructuring and technology advancements. The explosion of health information and new technologies occurring simultaneously with the shift of decision-making responsibility to patients/consumers is driving change in a challenging way. The potential for more relevant, focused and personalized care is evident; the potential risks to patients without a deep understanding of science and medicine are daunting. Attention to health literacy, patient-centered research and implementation science are essential to help us optimize the benefits of new approaches.
Ms. Kathleen Adams works 8-16 hours per week on iHealthscreen
Thomas Gerson, MBA
CFO
As a CFO, he raised more than $100M for his previous companies.
TERMS
iHealthScreen
Overview
PRICE PER SHARE
$2.63
DEADLINE
Aug 2, 2023
VALUATION
$24.98M
FUNDING GOAL
$10k - $1.23M
Breakdown
MIN INVESTMENT
$189.36
MAX INVESTMENT
$1,234,998.03
MIN NUMBER OF SHARES OFFERED
3,802
MAX NUMBER OF SHARES OFFERED
469,581
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives & Bonuses*
Time-Based:
Friends and Family Early Birds
Invest within the first 48 hours and receive 15% bonus shares.
Super Early Bird Bonus
Invest within the first week and receive 10% bonus shares.
Early Bird Bonus
Invest within the first two weeks and receive 5% bonus shares.
Amount-Based:
$1,000+ | Tier 1
Invest $1,000 and receive access 2% Bonus Shares.
$2,500+ | Tier 2
Invest $2,500 and receive access 3% Bonus Shares.
$5,000+ | Tier 3
Invest $5,000 and receive access 5% Bonus Shares.
$10,000+ | Tier 4
Invest $10,000 and receive access 10% Bonus Shares + zoom call with iHealthScreen’s founder.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
iHealthScreen, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.63 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $263. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company will not incur any irregular use of proceeds.
PRESS
ALL UPDATES
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Karl Stine
6 months ago
2
0